aldosterone antagonist

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to aldosterone antagonist: potassium sparing diuretics


 [al-dos´ter-ōn, al´do-ster-ōn″]
the main mineralocorticoid hormone secreted by the adrenal cortex, the principal biological activity of which is the regulation of electrolyte and water balance by promoting the retention of sodium (and, therefore, of water) and the excretion of potassium; the retention of water induces an increase in plasma volume and an increase in blood pressure. Its secretion is stimulated by angiotensin II.
aldosterone antagonist a compound that blocks the action of aldosterone; the group includes potassium sparing diuretics such as spironolactone that compete with aldosterone for receptor sites, thus blocking the aldosterone-dependent exchange of sodium and potassium in the distal tubule.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

al·dos·ter·one an·tag·o·nist

an agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, for example, spironolactone, are useful in treating the hypertension of primary hyperaldosteronism or the sodium retention of secondary hyperaldosteronism.
Farlex Partner Medical Dictionary © Farlex 2012

al·dos·ter·one an·tag·o·nist

(al-dos'tĕr-ōn an-tag'ŏ-nist)
An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents (e.g., spironolactone) are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

al·dos·ter·one an·tag·o·nist

(al-dos'tĕr-ōn an-tag'ŏ-nist)
Agent that opposes action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
Total patients receiving aldosterone antagonists in some form###33(47.1)
Initial observations indicated that aldosterone antagonists decrease left ventricular mass in patients with essential hypertension and left ventricular hypertrophy [37, 39] and improve myocardial function in hypertensive patients with diastolic heart failure [40].
And patients who qualified for TOPCAT on the basis of an elevated natriuretic peptide level had a primary endpoint rate of 15.9% with spironolactone, a highly significant 35% reduction compared with the 23.6% in controls, suggesting that an elevated baseline natriuretic peptide level may be a biomarker useful in identifying those HFpEF patients most likely to respond to an aldosterone antagonist.
In the first study, investigators noted that "landmark clinical trials" had shown the aldosterone antagonists spironolactone and eplerenone cut mortality by up to 30% and readmissions for HF by nearly 40% among patients who had heart failure accompanied by reduced ejection fraction.
This reluctance may in part be due to uncertainty about the safety and effectiveness of aldosterone antagonists under real-world conditions.
The Randomized Aldactone Evaluation Study (RALES) demonstrated a survival advantage with the aldosterone antagonist spironolactone (Aldactone) plus standard therapy in moderate to severe heart failure patients, while the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) did so in the post-MI/heart failure setting.
Still, aldosterone antagonists remain underutilized in heart failure patients in Europe as well as the United States.
The optional combination would be a thiazide and aldosterone antagonist.
About a third of the patients were also on treatment with an aldosterone antagonist, either spironolactone or eplerenone.
They are withholding continuous positive air pressure, a standard treatment for obstructive sleep apnea, from patients with the disorder and are instead treating them with spironolactone, an aldosterone antagonist. The goal is to see whether spironolactone alone is effective at relieving sleep apnea.
NEW YORK -- Evidence is accumulating that an aldosterone antagonist can be a safe and effective treatment for patients with refractory hypertension that has not responded to one or more agents from the first-line antihypertensive drug classes.
Harper uses in older women is spironolactone, an aldosterone antagonist that binds to the androgen receptor and inhibits androgen biosynthesis in the gonads and adrenal glands.